1. Introduction: Controlled Freezing as a Local Therapy
Cryoablation destroys tumors by freezing them. Like radiofrequency ablation, it is a minimally invasive, image-guided local therapy; unlike thermal ablation, it creates an «iceball» through cycles of freezing and thawing that damage cells and the tumor microvasculature. Cryoablation is established for small renal masses, selected liver and lung tumors, and some bone and soft-tissue lesions, and it is under study for focal prostate and breast disease. Its distinctive biological property is that freeze–thaw injury can release tumor antigens and provoke an immune response — an effect that has attracted research interest but is not yet a standard therapeutic strategy.
2. Mechanism of Cryoinjury
Cryoprobes exploit the Joule–Thomson effect: expanding argon gas cools the probe tip to approximately −160°C or below, while helium is used to thaw. In tissue, the resulting injury is multifactorial:
- Ice crystal formation causes mechanical disruption of cell membranes during both freezing and thawing.
- Dehydration and hypertonic injury occur as water leaves cells into the extracellular ice.
- Microvascular thrombosis interrupts blood supply, producing ischemic death of the frozen tissue.
- Apoptosis and immune activation may occur, particularly at the periphery of the iceball.
Repeated freeze–thaw cycles increase the completeness and extent of necrosis. The lethal temperature for most cells is around −40°C, and the goal is to extend the −40°C isotherm beyond the tumor margin.
3. Technique and Monitoring
One or more cryoprobes are placed into the tumor under ultrasound, CT, or MRI guidance. The forming iceball is visible on imaging and is monitored to ensure it encompasses the tumor with a margin. Multiple probes and active thawing allow larger and more complex ablation volumes. Cryoablation’s advantages over heat-based ablation include the visibility of the iceball in real time and the relative sparing of collagenous structures and large vessels (though vessels can still be injured).
4. Confirmed Clinical Evidence
4.1. Renal Cell Carcinoma
Cryoablation is a guideline-endorsed option for small renal masses (clinical stage T1a), particularly in patients who are poor surgical candidates or who have a solitary kidney, and it may be considered in some patients as an alternative to partial nephrectomy. Comparative studies report good oncologic control for small tumors, with slightly higher rates of local recurrence than surgery but lower procedural morbidity — a trade-off reflected in patient selection.
4.2. Liver Tumors
Cryoablation is used for hepatocellular carcinoma and selected liver metastases. Historically it was associated with «cryoshock» (a systemic inflammatory reaction with hypotension, coagulopathy, and organ dysfunction) more often than heat-based techniques, and its use on the liver declined in many centers relative to microwave and radiofrequency ablation. In experienced hands it remains an option for suitable lesions.
4.3. Other Sites
Cryoablation is used for some lung tumors, painful bone metastases, soft-tissue lesions, and in focal or salvage therapy for prostate cancer. In breast cancer, focal cryoablation is under study for selected small tumors. The strength of the evidence varies by site, with the most robust data in kidney and bone.
5. Early Research and Emerging Approaches
- Cryoimmunology. Cryoablation can release tumor antigens and has been proposed to stimulate systemic antitumor immunity. Case reports of regression of untreated lesions («abscopal»-like effects) exist, but whether this can be reliably combined with immunotherapy to produce clinical benefit is unproven.
- Focal therapy for prostate cancer using cryoablation aims to treat only the index lesion; durability and appropriate selection remain to be established.
- Breast focal cryoablation for small, well-selected tumors is early-phase.
6. Limitations and Complications
Complications include bleeding, injury to adjacent structures (ureter, bowel, bile ducts), tract seeding (rare), and, historically, cryoshock. Efficacy falls with increasing tumor size, and proximity to large vessels (the «heat-sink» analogue — in this case warming by blood flow) can limit the lethal isotherm. Cryoablation is a local therapy; it does not address micrometastatic disease.
7. Unresolved Questions and Speculative Directions
- Whether cryoablation’s immune effects can be therapeutically harnessed (for example, with checkpoint inhibitors) is speculative and under active investigation.
- Comparative effectiveness against partial nephrectomy, microwave ablation, and other modalities for specific tumors is informed by observational data more than by large randomized trials. [Marked for verification.]
8. Conclusion
Cryoablation is an established minimally invasive therapy that destroys tumors through freeze–thaw injury and microvascular thrombosis. It is a guideline-endorsed option for small renal masses, is used for selected liver, lung, bone, and prostate lesions, and offers the practical advantage of a visible, monitorable iceball. Its limitations are size-dependence, potential cryoshock, and local-only scope. The possibility of using cryoablation to trigger systemic antitumor immunity is scientifically intriguing but remains early and unproven.
Sources and Key Research Centers
- National Cancer Institute — cryosurgery/ablation overviews.
- American Urological Association (AUA) — guidelines on small renal masses and localized renal cancer.
- Cardiovascular and Interventional Radiological Society of Europe (CIRSE) — standards for percutaneous ablation.
- Small renal masses: ablation vs surgery — AUA and EAU guideline analyses of thermal ablation including cryoablation. [Citation details to be verified.]
- Cryoimmunology and abscopal effects — case reports and early clinical series. [Citation details to be verified; treat as preliminary.]
- ClinicalTrials.gov — ongoing trials of focal cryoablation and cryoablation plus immunotherapy (search terms: cryoablation, focal therapy prostate cryoablation).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.